Transient downmodulation of CD20 by rituximab.

被引：0
|
作者：
Jilani, I [1 ]
O'Brien, S [1 ]
Manshouri, T [1 ]
Thomas, DA [1 ]
Thomazy, VA [1 ]
Imam, M [1 ]
Naeem, S [1 ]
Verstovsek, S [1 ]
Kantarjian, H [1 ]
Giles, F [1 ]
Keating, M [1 ]
Albitar, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3174
引用
收藏
页码：804A / 804A
页数：1
相关论文
共 50 条
  • [41] Intratissutal effects of anti CD20 rituximab (RTX) in a patient with Graves' ophtalmopathy
    Bonara, P.
    Frugoni, C.
    Vannucchi, G.
    Campi, I.
    Rossi, S.
    Sbrozzi, C.
    Salvi, M.
    Beck-Peccoz, P.
    CYTOMETRY PART A, 2008, 73A (01) : 88 - 89
  • [42] Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab)
    Nakagawa, Y
    Ikeda, U
    Hirose, M
    Ubukata, S
    Katsuki, T
    Kaminishi, Y
    Saito, T
    Hironaka, M
    Izumi, T
    Shimada, K
    CIRCULATION JOURNAL, 2004, 68 (02) : 172 - 173
  • [43] Chop with rituximab-treatment option in CD20(+) NHL - Our experience
    Utracka-Hutka, B
    Polakiewicz-Gilowska, A
    Cedrych, I
    ANNALS OF ONCOLOGY, 2005, 16 : 154 - 154
  • [44] 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: A case report
    Tsutsumi Y.
    Ohigashi H.
    Ito S.
    Shiratori S.
    Teshima T.
    Journal of Medical Case Reports, 10 (1)
  • [45] Targeting CD20
    Winter, JN
    BLOOD, 2003, 101 (11) : 4227 - 4227
  • [46] CD20: A review
    Chang, KL
    Arber, DA
    Weiss, LM
    APPLIED IMMUNOHISTOCHEMISTRY, 1996, 4 (01): : 1 - 15
  • [47] Structural changes in the internal domain of CD20 antigen associated with the emergence of rituximab resistance: Effects of proteasome inhibition in CD20 structure and rituximab anti-tumor activity in rituximab-resistant cell lines (RRCL).
    Hernandez-Ilizaliturri, FJ
    Olejniczak, SH
    Knight, J
    Czuczman, MS
    BLOOD, 2005, 106 (11) : 425A - 425A
  • [48] SRC INHIBITORS DOWNREGULATE CD20 AND MODULATE THE ACTIVITY OF THE CD20 PROMOTER
    Winiarska, M.
    Bojarczuk, K.
    Pyrzynska, B.
    Miazek, N.
    Zapala, P.
    Bobrowicz, M.
    Dwojak, M.
    Siernicka, M.
    Golab, J.
    HAEMATOLOGICA, 2014, 99 : 45 - 45
  • [49] CD20抗原及治疗性抗CD20抗体
    王玉刚
    沈倍奋
    中国肿瘤生物治疗杂志, 2005, (01) : 76 - 79
  • [50] Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101vs. the Type I CD20 Antibodies Rituximab and Ofatumumab
    Herter, Sylvia
    Waldhauer, Inja
    Otz, Tina
    Herting, Frank
    Lang, Sabine
    Nicolini, Valeria
    Roemmele, Michaela
    Friess, Thomas
    Van Puijenbroek, Erwin
    Bacac, Marina
    Weidner, K. Michael
    Gerdes, Christian
    Umana, Pablo
    Klein, Christian
    BLOOD, 2010, 116 (21) : 1601 - 1601
12345